News & Article

Oncology is shifting fast. Base your clinical strategy on predictive cell testing, not animal studies. Identify the right tumors early and avoid dead ends.

The biotome may impact response to immunotherapy. Could it become a new predictive biomarker in oncology? A look at recent scientific insights.

FDA’s exemption challenges phase 2 design in oncology. Should we move away from animal models and focus on early, cell-level clinical analysis?

Good news for animal welfare: the FDA has eased preclinical requirements

This simplified case study is inspired by real-world challenges

Immunotherapies have transformed cancer prognostic, and they’re reshaping early-phase clinical development too, demanding new strategies.

Your pitch to investors is about your innovation. Great ! But what if they are expecting something else (the CMO speaking) ?

In oncology, what if you design your phase 2 and the trajectory to phase 3 …. starting already from the in vitro stage ?

Can the microbiome silently impact immuno-oncology trials? Discover how it may influence your phase 1/2 study outcomes without being on your radar.

One new EMA/FDA approval EVERY 5 MONTHS. This means faster changes in standards of care, and in future phase 3 comparators.

Immunotherapy is no longer a last-resort option. It is now integrated earlier into cancer treatment, but at what cost for molecules in development?